The mobilizing potential and therapeutic activity of ifosfamide/vinorelbine-containing regimens with G-CSF support were explored in patients with pretreated malignant lymphomas. Ten patients with non-Hodgkin's lymphoma (NHL) received ifosfamide and vinorelbine, and 17 with Hodgkin's disease (HD) received ifosfamide, vinorelbine and gemcitabine (IGEV regimen), as induction chemotherapy before high-dose chemotherapy (HDT) with peripheral blood stem cell (PBSC) support. Most of the patients had been heavily pretreated with various chemotherapy regimens ± radiotherapy. The target yield was у3 × 10 6 CD34 + cells/kg of body weight in order to support the subsequent myeloablative chemotherapy. The optimal PBSC harvest occurred on days 11 and 12, with no difference in CD34 Despite the high curability rate of aggressive non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD) with front-line therapy, only a small fraction of patients with refractory or relapsing disease can be successfully managed using standard-dose salvage chemotherapy. The encouraging results of high-dose therapy (HDT) with peripheral blood stem cell (PBSC) support have been widely demonstrated in both diseases.
Despite the high curability rate of aggressive non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD) with front-line therapy, only a small fraction of patients with refractory or relapsing disease can be successfully managed using standard-dose salvage chemotherapy. The encouraging results of high-dose therapy (HDT) with peripheral blood stem cell (PBSC) support have been widely demonstrated in both diseases. 1, 2 Over the last few years, PBSCs have come to be preferred over autologous bone marrow because of their ability to shorten the myelosuppressed period, accelerate engraftment of both neutrophils and platelets, and reduce blood product and antibiotic requirements. 3, 4 Hematopoietic growth factors with or without high-dose cyclophosphamide are considered standard procedures for adequate mobilization of PBSCs, 5 although other combinations of chemotherapy and growth factors have also been used. A number of studies have demonstrated the superiority of the combination of chemotherapy and growth factors over either element alone, as well as the correlation between the intensity of the chemotherapy with the number of mobilized PBSCs. [6] [7] [8] [9] [10] [11] The best option is therefore a regimen that embodies both proven mobilizing and adequate antineoplastic activity.
The efficacy of ifosfamide and/or vinorelbine-based chemotherapy as salvage regimens for poor prognosis lymphoma has also been demonstrated. [12] [13] [14] [15] [16] [17] [18] Gemcitabine has recently been shown to be active in heavily pretreated HD patients, with a response rate of 40% and a low level of drug-related toxicity. 19 The aim of this study was to determine the efficacy of ifosfamide/vinorelbine-based regimens and G-CSF in PBSC mobilization. We also investigated the optimal timing of progenitor cell collection, the yield collected, the adverse effects of the mobilization regimens and the time to hematopoietic reconstitution after myeloablative therapy.
Patients and methods

Patients
Between November 1997 and May 2000, 27 consecutive patients with refractory-relapsed malignant lymphoma (16 males and nine females: median age 41.1 years; range 21-65) were assigned to the high-dose program. Most of the patients had been pretreated with a median of two chemotherapeutic regimens (range 1-4). Thirteen (10 HD and three NHL) had also received extended-field radiotherapy (Table 1) . + cell count was reached after the mobilization course. Four courses of chemotherapy were planned, provided that there was evidence of at least partial remission after the second cycle.
Chemotherapy
In order to explore the mobilizing capacity of the regimen, PBSC collection was performed after the first or second course in the first 13 patients, and after documentation of an objective response (third course) thereafter.
Patients with an adequate PBSC collection and objective response underwent myeloablative therapy with thiotepa (600 mg/m 2 on day −3) and melphalan (140 mg/m 2 on day −1). The cryopreserved PBSCs were thawed and reinfused on day 0. Post-reinfusion G-CSF was planned if fewer than 5 × 10 6 CD34 + cells/kg were reinfused, or if required for clinical reasons.
Leukapheresis and cryopreservation
All of the patients underwent a routine full blood examination every other day starting from day 5 after each chemotherapy course. During the mobilization cycle, daily peripheral blood CD34
+ monitoring was started when the absolute neutrophil count (ANC) reached 1 × 10 9 /l, and apheresis when the peripheral blood CD34
+ cell count exceeded 10 cells/l. The CD34 cells were harvested 10-14 days after chemotherapy using a COBE Spectra separator (COBE, Lakewood, CO, USA), software version 5.1 and 6.0, with a collection pump speed of 2400 g/min. The blood was collected via a central venous access device or from peripheral veins, and 2.7 times the patient's estimated blood volume was processed. The cells were cryopreserved using a Nicol Plus PC device (Air Liquide, Bussey St Georges, France) and a mixture of autologous plasma and DMSO (Merck Kga A, Darmstad, Germany; final concentration 10%), and then stored in liquid nitrogen.
The selected threshold for a satisfactory harvest was у3 × 10 6 CD34 + cells/kg.
CD34 + cell estimates
An aliquot of 0.5-1 × 10 6 cells of peripheral blood and leukapheresis product was incubated for 20 min at 4°C with 20 ml of the anti-HPCA-2 monoclonal antibody conjugated with phycoerythrin (Becton Dickinson, San Jose, CA, USA). The red cells were lysed using Autolyse Plus (Becton Dickinson) and then washed twice. Samples incubated with mouse IgG1 antibody conjugated with phycoerythrin were used as the isotype control. Flow cytometry was performed using a FACScan (Becton Dickinson) software System II. The flow rate was kept between 200 and 400 cells. Debris was gated out using the forward scatter descriminator, and the leukocytes gated on the basis of their forward/side scattering characteristics. CD34
+ cells were identified on a dot-plot of log fluorescence vs side, as a distinct population positioned above the isotypic controlstained cells, and had the same side scatter intensity as mononuclear cells: 10 6 cells were usually evaluated. The results were expressed as CD34
+ cells/l and CD34 + cells/kg.
CFU-GM
One × 10 5 cells were resuspended in 1 ml of methylcellulose culture medium (MethoCult H4533, Stem Cell Technologies, Vancouver, Canada) containing 1% methylcellulose, 30% FBS, 1% BSA, 5% PHA-LCM, 10 4 mercaptoethanol and 2 mm l-glutamine, plated in quadruplicate, and incubated at 37°C, 5% CO 2 , in a fully humidified atmosphere. The colonies were counted after 14 days of culture.
Statistical analysis
Spearman's correlation test was used to compare CD34 cells/l and CD34 leukapheresis product, and to compare CD34/l and CFU-GM/kg. The Mann-Whitney U test was used to compare the influence of the different chemotherapies and diseases on CD34/kg, CFU-GM/kg and the day of platelet and neutrophil recovery after high-dose therapy.
Response criteria
Response to therapy was assessed by means of clinical and radiologic examination. Complete remission (CR) was defined as the disappearance of any bulky disease for at least 1 month, and partial remission (PR) as at least a 50% decrease in tumour burden. Any other situation was considered a non-response (NR).
Results
Time to PBSC collection
As shown in Table 2 , most of the patients had peak CD34 + cell levels on day 12, with a wide range of detectable levels of CD34
+ cells from days 10 to 14 after chemotherapy. No difference was observed between patients with HD or NHL.
Mobilization efficacy
The median number of collected CD34 + cells was 10.9 × 10 6 /kg (range 1.76-61.1). The proposed number of CD34 + cells could be collected after one apheretic procedure in 60% of patients, and after two procedures in 89%. The target yield of mobilized CD34
+ cells was reached in 24 of the 27 patients. The median number of CFU-GM in the whole series was 128 × 10 4 /kg (7.2-665), and significantly correlated with the number of CD34 + /l. No significant differences in mobilization ability were observed between the patients with HD or NHL.
Side-effects
There were as no treatment-related hospitalizations or toxic deaths. Grade III-IV neutropenia occurred during 45% of the courses and thrombocytopenia (Ͻ50 000/ml) during 25%, with one patient requiring platelet transfusion. Grade III-IV anemia occurred during 21% of courses, with one patient being transfused with two red blood cell units. Only four courses were delayed because of hematological toxicity, and there were minimal non-hematological side-effects.
Engraftment
Fifteen of the 27 patients (12 HD and three NHL) have so far undergone high-dose therapy with PBSC reinfusion. They were reinfused with a median of 9.8 × 10 6 cells/kg (range 3.22-23.2), and 10 were also given post-transplant G-CSF. Absolute neutrophil count (ANC, Ͼ500/l for 2 consecutive days) and platelet recovery (Ͼ20 000/l for 2 consecutive days without transfusions) were achieved after a median of, respectively, seven (range 6-11) and 14.5 days (range 0-106). No correlation was found between the num- Bone Marrow Transplantation ber of CFU-GM or CD34 + cells reinfused and the number of days to engraftment.
Clinical outcome
Of the 17 patients with HD, 10 achieved CR, five PR and two showed NR: the overall response rate was 94%. Of the 10 NHL patients, only four (40%) achieved a PR.
Fifteen patients have so far received high-dose chemotherapy with PBSC support. High-dose consolidation converted PR to CR in three NHL patients and thus, after transplantation, 13 were in CR (10 HD and three NHL) and two in PR.
At present, 10/27 patients are alive and disease-free, 10 are alive with disease (seven still on treatment) and seven have died of lymphoma.
Discussion
High-dose chemotherapy with PBSC support is widely used in the management of patients with relapsed/refractory malignant lymphomas. Salvage chemotherapy in such patients should ensure good antilymphoma activity, as well as proper PBSC collection. There is general agreement concerning the combination of high (5-7 g/m ) doses of cyclophosphamide and G-CSF as the optimal mobilizing strategy for hemato-oncologic disorders, 21 whereas lower single-dose (1.5 g/m 2 ) cyclophosphamide with G-CSF does not allow adequate CD34 + cell collection. 22 As cyclophosphamide is widely used in most first-line regimens for lymphomas, the use of other drugs and regimens with mobilizing and cytoreductive aims is justified at relapse, with ifosfamide beeing one of the main compound. 23, 24 However, some of these schedules are excessively toxic and others do not allow adequate PBSC mobilization. Two groups have used the MIME regimen (mitoguazon, ifosfamide with MESNA, etoposide) and reported a high toxicity profile 25 with relatively low mobilising efficacy. 26 Petit et al 27 have used ESHAP regimen (etoposide, aracytin and cisplatin) in 22 patients with a 90% mobilizing activity and a median PBSC collection of 7.4 × 10 6 CD34 + cells/kg. Otherwise grade III-IV neutropenia occurred in 54% and fever in 18% of cases. 27 No clinical data about response rate were reported. . More than 50% of patients received red blood cell transfusions and 30% at least one platelet transfusion. 28 In our report, ifosfamide and vinorelbine-based regimens show good mobilizing activity as 89% of our patients yielded as many as 13.6 × 10 6 CD34 + cells/kg (ranging from 1.76 to 61.1) together with a response rate of 94% in HD and 40% in NHL. It has been reported that the amount of previous chemotherapy and irradiation negatively influences the yield of mobilized CD34 cells but, in line with some reports (but not all) we found that neither influenced the yield of CD34 cells. Moreover, hematological toxicity was low: grade III-IV neutropenia occurred during 45% of courses, thrombocytopenia Ͻ50 000/ml during 25%, and grade III-IV anemia during 21%. There were neither treatmentrelated hospitalizations nor toxic deaths. All of the patients receiving high-dose therapy experienced rapid neutrophil and platelet engraftment, and 85% achieved a CR within completion of the treatment program.
Disease status at transplantation is currently considered the main prognostic factor for therapeutic outcome, 29 and this justifies the use of regimens with both mobilizing and cytoreductive activity. The ifosfamide/vinorelbine-based regimens induced a high response rate in heavily pretreated HD patients. Otherwise the addition of other active drugs, such as cytarabine and/or platinum compounds, seems to be essential in order to improve the response rate in NHL patients.
In conclusion, our data support the use of an ifosfamide/vinorelbine-based regimen as salvage therapy in the pre-transplant induction phase for heavily pretrated Hodgkin's and non-Hodgkin's lymphomas. The high number of PBSCs may contribute towards the development of novel therapeutic approaches such as tandem transplantation and/or a better selection of CD34 + cells. 30 
